Eisai Provides Lenvatinib Dose Reductions at No Cost

On May 10, 2022, it was announced that the Eisai lenvatinib dose exchange program has been expanded to cover all indicated dose reductions for patients with endometrial cancer who require a new prescription. The program will allow dose exchanges for up to 15 days of a patient's current dose for one that is lower, once per quarter, and at no cost.

For more information, read the news article.

Posted 5/12/2022